For as long as cancer has been studied, its deadliest act — the migration of malignant cells through the bloodstream to colonize distant organs — has resisted clear observation in human tissue. In August 2026, researchers at Columbia Engineering announced a multi-organ chip, small enough to hold in one hand, that replicates this journey using actual human bone and lung tissue grown from stem cells. The device does not merely simulate metastasis; it makes visible a process responsible for two-thirds of all cancer deaths, offering science something it has long lacked: a human mirror in which to
News-Medical
· Aug 20, 2026
· health
· 4 min de lectura
High
Verificación: Verificado
Columbia engineers develop first multi-organ chip to model cancer metastasis in human tissue
Metastasis is responsible for at least two-thirds of cancer deaths, representing a major source of cancer mortality globally.
◉
Health & Medicine
8180 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% coincidencia
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% coincidencia
Cobertura Relacionada
CBS News · Aug 21
Nashville hospital drug mix-up leaves 4 patients with severe complications
Four patients at a Nashville hospital received potassium instead of pain medication during routine joint replacement sur…
BBC News · Aug 21 UK warns vulnerable groups to avoid runny eggs amid salmonella outbreakUK health authorities warn vulnerable populations to avoid undercooked eggs at restaurants due to a rapidly expanding sa…
BBC News · Aug 21 Meghan in talks for Netflix's The Gentlemen as she considers return to actingMeghan is in early talks to return to acting with a role in Netflix's The Gentlemen, marking her first significant actin…
The Pharmaceutical Journal · Aug 21 Survey reveals aesthetic goals driving weight-loss medication use over health concernsA UK survey shows 78% of respondents would consider weight-loss medications for weddings and holidays rather than health…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Columbia University develops multi-organ chip for cancer metastasis research, reducing reliance on animal models and potentially accelerating drug development with human-based alternatives.
Escalation Risk
low
Confidence
HIGH
United States
European Union
Global pharmaceutical industry
This advancement strengthens U.S. biomedical research leadership and may shift competitive advantage in oncology drug development toward institutions with organ-chip technology. Could reduce dependence on animal testing, affecting regulatory frameworks globally and positioning early adopters as innovation leaders in precision medicine.
Similar to how in vitro fertilization (IVF) technology shifted reproductive medicine from animal models to human-based systems in the 1970s-80s, establishing new research paradigms and regulatory standards.
Lente Económico
📈
Columbia's multi-organ chip technology offers a human-based cancer metastasis model, potentially accelerating drug development and reducing reliance on animal testing, with significant implications for biotech and pharmaceutical R&D efficiency.
Market Signal
bullish
Confidence
HIGH
Biotechnology and Life Sciences
Pharmaceutical Development
Medical Devices
Healthcare and Oncology
Contract Research Organizations (CROs)
Laboratory Equipment Manufacturing
Consumers may benefit from faster development of more effective cancer treatments with fewer clinical failures, potentially reducing time-to-market for metastatic cancer therapies and improving treatment outcomes for cancer patients.
Regulatory agencies (FDA, EMA) may accelerate adoption of organ-on-chip models as alternatives to animal testing, potentially reducing regulatory timelines for drug approval. This could influence animal testing regulations and research funding priorities toward human-based modeling technologies.